IP Library Granted Patent US 10,357,467
Granted Patent B2
US 10,357,467 · App. 15/992,453 · Granted Jul 23, 2019

All-natural enteric soft capsules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,357,467
App. No.
15/992,453
Granted
Jul 23, 2019
Kind
B2
Abstract

Described herein are soft capsules and enteric soft capsules comprising cationic Type A gelatin and acid insoluble enteric polymers. In particular, the compositions and methods for manufacturing all-natural enteric soft capsules comprising Type A gelatin and matrix fills are described. In one embodiment, the enteric soft capsules comprise active ingredients such as non-steroidal anti-inflammatory drugs (NSAIDs). In another embodiment, the enteric soft capsule comprises matrix fills of omega-3 fatty acids.

Claims (10)

1. A method for manufacturing an enteric soft capsule, the method comprising:

(a) combining 20% to 40% Type A gelatin by mass 2% to 7% pectin by mass, and 8% to 30% glycerol by mass with heating to form a gel mass with a viscosity of 20,000 cP to 30,000 cP;

(b) forming the enteric soft capsule from the gel mass using rotary die technology; and

(c) adding a fill comprising one or more active ingredients to the enteric soft capsule;

wherein the obtained enteric soft capsule consists of gelatin Type A, pectin, glycerol, and one or more active ingredients.

2. The enteric soft capsule formed by the method of claim 1 .

3. The capsule of claim 2 , wherein the capsule does not dissolve in simulated gastric fluid having a pH of 1.2 for at least 2 hours, and begins dissolution in simulated intestinal fluid having a pH of 6.8 within about 10 minutes.

4. The capsule of claim 2 , wherein the fill comprising one or more active ingredients comprises fish oil or a non-steroidal anti-inflammatory drug.

5. The capsule of claim 4 , wherein the fish oil comprises eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and one or more fat-soluble vitamins.

6. The capsule of claim 4 , wherein the non-steroidal anti-inflammatory drug comprises diclofenac.